IL319486A - Hsd17b13 inhibitors and/or degraders - Google Patents

Hsd17b13 inhibitors and/or degraders

Info

Publication number
IL319486A
IL319486A IL319486A IL31948625A IL319486A IL 319486 A IL319486 A IL 319486A IL 319486 A IL319486 A IL 319486A IL 31948625 A IL31948625 A IL 31948625A IL 319486 A IL319486 A IL 319486A
Authority
IL
Israel
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
recited
fluoro
Prior art date
Application number
IL319486A
Other languages
Hebrew (he)
Inventor
Jan Antoinette Cusi Romero Adams
Bruce Michael Bechle
Jason Kenneth Dutra
David James Edmonds
Michelle Renee Garnsey
Xinjun Hou
Jisun Lee
Ii Deane Milford Nason
Steven Victor O'neil
Danica Antonia Rankic
Yang Wang
Ann Sorrentino Wright
Lei Zhang
Liying Zhang
Original Assignee
Pfizer
Jan Antoinette Cusi Romero Adams
Bruce Michael Bechle
Jason Kenneth Dutra
David James Edmonds
Michelle Renee Garnsey
Xinjun Hou
Jisun Lee
Ii Deane Milford Nason
Oneil Steven Victor
Danica Antonia Rankic
Yang Wang
Ann Sorrentino Wright
Lei Zhang
Liying Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Jan Antoinette Cusi Romero Adams, Bruce Michael Bechle, Jason Kenneth Dutra, David James Edmonds, Michelle Renee Garnsey, Xinjun Hou, Jisun Lee, Ii Deane Milford Nason, Oneil Steven Victor, Danica Antonia Rankic, Yang Wang, Ann Sorrentino Wright, Lei Zhang, Liying Zhang filed Critical Pfizer
Publication of IL319486A publication Critical patent/IL319486A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (23)

1. 1
2. CLAIMSWHAT IS CLAIMED IS: 1. A compound of Formula I
3. Formula I wherein A is -NH-C(O)- or a heteroaryl having 1, 2, 3, or 4 heteroatoms selected from O, N, and S and wherein A is optionally substituted with one or two R; B is absent or is H, aryl, heteroaryl, heterocyclyl, fluoro, chloro, bromo, oxo, cyano, hydroxyl, (C1-C6)alkyl, (C 3-C6)cycloalkyl, (C1-C6)fluoroalkyl, (C1-C6)alkoxy, or (C1-C6)fluoroalkoxy, wherein the heteroaryl or heterocyclyl has 1, 2, or 3 heteroatoms selected from O,N, and S and wherein B is optionally substituted with one or two R; C is absent or is H, -NH-C(O)-R, -S(O)2-R, -O-S(O)2-R, fluoro, chloro, bromo, oxo, cyano, hydroxyl, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, (C3-C6)cycloether, (C1-C6)fluoroalkyl, (C1-C6)fluoroalkoxy, aryl, heteroaryl or heterocyclyl, wherein the heteroaryl or heterocyclyl has 1, 2, or 3 heteroatoms selected from O,N, and S, and wherein C is optionally substituted with one, two or three R; R, R, and Rare each independently selected from H and fluoro; each R, R and R are independently selected from oxo, hydroxyl, chloro, fluoro, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)fluoroalkyl, (C3-C6)cycloalkyl, and heterocyclyl having 1, 2, or 3 heteroatoms selected from O and N; Ris hydroxyl, chloro, fluoro, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)fluoroalkyl, or (C3-C6)cycloalkyl; and n is 0, 1 or 2; or a pharmaceutically acceptable salt of said compound. 2. A compound as recited in claim 1, wherein the compound has the Formula IA 1
4. Formula IA or a pharmaceutically acceptable salt of said compound. 3. A compound as recited in claim 1, wherein the compound has the Formula IB
5. Formula IB or a pharmaceutically acceptable salt of said compound. 4. A compound as recited in any of the preceding claims, wherein at least one of R, R, and R are fluoro; or a pharmaceutically acceptable salt of said compound. 5. A compound as recited in any of the preceding claims, wherein A is thiazolyl, pyrazolyl, oxazolyl, imidazolyl, isoxazolyl, isothiazolyl, imidazotriazinyl, imidazopyridazinyl, imidazopyridinyl, benzoimidazolyl, benzothiazolyl, purinyl, pyridopyridazinyl, quinazolinyl, indazolyl, imidazopyridinyl, benzooxazolyl, pyrazolopyridinyl, isoindolinonyl, triazolyl, or oxadiazolyl, or a pharmaceutically acceptable salt of said compound. 1
6. A compound as recited in any of the preceding claims, wherein
7. A is , , , , , , , , , or , or a pharmaceutically acceptable salt of said compound. 7. A compound as recited in any of the preceding claims, wherein B is absent or is H, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrazolyl, piperazinyl, quinoxalinyl, phenyl, triazolyl, thiazolyl, thiadiazolyl, oxazolyl, imidazolyl, indazolyl, (C 1-C6)alkyl, (C1-C6)fluoroalkyl, (C1-C6)alkoxy, bromo, chloro, fluoro, or oxo, and wherein B is optionally substituted with one or two fluoro, oxo, hydroxyl, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)fluoroalkyl, (C1-C6)alkoxy, or (C3-C6)cycloether; or a pharmaceutically acceptable salt of said compound.
8. A compound as recited in any of the preceding claims, wherein B is pyrimidinyl, (C1-C3)fluoroalkyl substituted pyrimidinyl, (C1-C3)alkyl substituted pyrazolyl, methoxy substituted pyridazinyl, difluoromethyl substituted pyrazinyl, trifluoromethyl substituted pyrimidinyl, or methoxy substituted pyrimidinyl; or a pharmaceutically acceptable salt of said compound.
9. A compound as recited in any of the preceding claims, wherein C is absent or is H, pyridinyl, piperazinyl, oxolanyl, (C3-C6)cycloalkyl, (C1-C6)alkyl, (C1-C6)fluoroalkyl, (C1-C6)alkoxy, cyano, bromo, chloro, fluoro, or oxo, and wherein C is optionally substituted with one, two or three fluoro, oxo, hydroxyl, (C 1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)fluoroalkyl, or (C1-C6)alkoxy; 1 or a pharmaceutically acceptable salt of said compound.
10. A compound as recited in any of the preceding claims, wherein C is absent or is pyridinyl, piperazinyl, (C3-C6)cycloalkyl, (C1-C6)alkyl, (C1-C6)fluoroalkyl; and wherein C is optionally substituted with one, two or three fluoro, oxo, hydroxyl, or (C 1-C6)alkyl; or a pharmaceutically acceptable salt of said compound.
11. A compound wherein the compound is 2,3,5-Trifluoro-4-hydroxy-N-[(4-{3-[5-(trifluoromethyl)pyrimidin-2-yl]-1,2,4-oxadiazol-5-yl}bicyclo[2.2.2]octan-1-yl)methyl]benzamide; 2,3,5-Trifluoro-4-hydroxy-N-({4-[6-(pyrimidin-2-yl)-2H-indazol-2-yl]bicyclo[2.2.2]octan-1-yl}methyl)benzamide; 2,3,5-Trifluoro-4-hydroxy-N-({(1r,4r)-4-[6-(pyrimidin-5-yl)-2H-indazol-2-yl]cyclohexyl}methyl)benzamide; 2,3,5-Trifluoro-4-hydroxy-N-({4-[3-(6-methoxypyridazin-3-yl)-1,2,4-oxadiazol-5-yl]bicyclo[2.2.2]octan-1-yl}methyl)benzamide: N-[(4-{5-[5-(Difluoromethyl)pyrazin-2-yl]-1,2,4-oxadiazol-3-yl}bicyclo[2.2.2]octan-1-yl)methyl]-3,5-difluoro-4-hydroxybenzamide; 3,5-Difluoro-4-hydroxy-N-{[(1r,4r)-4-{3-[5-(trifluoromethyl)pyrimidin-2-yl]-1,2,4-oxadiazol-5-yl}cyclohexyl]methyl}benzamide; 3,5-Difluoro-4-hydroxy-N-({(1r,4r)-4-[6-(2-methoxypyrimidin-5-yl)-2H-pyrazolo[4,3-c]pyridin-2-yl]cyclohexyl}methyl)benzamide, 2,3,5-Trifluoro-4-hydroxy-N-[(4-{5-[2-(piperazin-1-yl)pyrimidin-4-yl]-1,2,4-oxadiazol-3-yl}bicyclo[2.2.2]octan-1-yl)methyl]benzamide, or 2,3,5-Trifluoro-4-hydroxy-N-[(4-{5-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-1,2,4-oxadiazol-3-yl}bicyclo[2.2.2]octan-1-yl)methyl]benzamide, or a pharmaceutically acceptable salt of said compound.
12. A compound wherein the compound is 2,3,5-Trifluoro-4-hydroxy-N-[(4-{5-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-1,2,4-oxadiazol-3-yl}bicyclo[2.2.2]octan-1-yl)methyl]benzamide, or a pharmaceutically acceptable salt of said compound.
13. A compound wherein the compound is 2,3,5-Trifluoro-4-hydroxy-N-[(4-{5-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-1,2,4-oxadiazol-3-yl}bicyclo[2.2.2]octan-1-yl)methyl]benzamide, hydrochloride salt.
14. A compound wherein the compound is 1
15. . 15. A compound according to any of claims 1-14 or a pharmaceutically acceptable salt of said compound for use in a method of treating fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with cirrhosis, nonalcoholic steatohepatitis with cirrhosis, hepatocellular carcinoma, alcoholic fatty liver disease, alcoholic steatohepatitis, hepatitis B, hepatitis C, biliary cirrhosis, kidney renal clear cell carcinoma, head and neck squamous cell carcinoma, colorectal adenocarcinoma, mesothelioma, stomach adenocarcinoma, adrenocortical carcinoma, kidney papillary cell carcinoma, cervical and endocervical carcinoma, bladder urothelial carcinoma, lung adenocarcinoma, Type I diabetes, idiopathic Type I diabetes (Type Ib), latent autoimmune diabetes in adults (LADA), early-onset Type 2 diabetes (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, skin and connective tissue disorders, foot ulcerations and ulcerative colitis, endothelial dysfunction and impaired vascular compliance, kidney disease, end-stage kidney disease, chronic kidney disease at risk of progression, and maple syrup urine disease.
16. The compound for use as recited in claim 15 wherein alcoholic fatty liver disease, alcoholic steatohepatitis, hepatitis B, hepatitis C, or biliary cirrhosis is treated.
17. The compound for use as recited in claim 15 wherein fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with cirrhosis or nonalcoholic steatohepatitis with cirrhosis or hepatocellular carcinoma is treated. 1
18. The compound for use as recited in claim 15 wherein nonalcoholic steatohepatitis is treated.
19. A compound according to any of claims 1-14 or a pharmaceutically acceptable salt of said compound for use in a method of reducing the development of liver cirrhosis, cirrhotic decompensation, progression to model of end-stage liver disease (MELD), liver transplant, liver-related death, or hepatocellular carcinoma.
20. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of any of claims 1-14 or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable carrier, vehicle or diluent.
21. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising: a first compound, said first compound being a compound of any of claims 1-or a pharmaceutically acceptable salt of said compound; a second compound, said second compound being an anti-diabetic agent; a non-alcoholic steatohepatitis treatment agent, a non-alcoholic fatty liver disease treatment agent or an anti-heart failure treatment agent and a pharmaceutical carrier, vehicle or diluents.
22. The pharmaceutical combination composition as recited in claim 21 wherein said non-alcoholic steatohepatitis treatment agent or non-alcoholic fatty liver disease treatment agent is an ACC inhibitor, a KHK inhibitor, a DGAT-2 inhibitor, an FXR agonist, metformin, incretin analogs, or an incretin receptor modulator.
23. The pharmaceutical combination composition as recited in claim 21 wherein said anti-diabetic agent is an SGLT-2 inhibitor, metformin, incretin analogs, an incretin receptor modulator, a DPP-4 inhibitor, or a PPAR agonist.
IL319486A 2022-10-07 2023-10-05 Hsd17b13 inhibitors and/or degraders IL319486A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263378807P 2022-10-07 2022-10-07
PCT/IB2023/059988 WO2024075051A1 (en) 2022-10-07 2023-10-05 Hsd17b13 inhibitors and/or degraders

Publications (1)

Publication Number Publication Date
IL319486A true IL319486A (en) 2025-05-01

Family

ID=88315393

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319486A IL319486A (en) 2022-10-07 2023-10-05 Hsd17b13 inhibitors and/or degraders

Country Status (9)

Country Link
US (1) US20240150334A1 (en)
EP (1) EP4598908A1 (en)
JP (1) JP2025533088A (en)
KR (1) KR20250075705A (en)
CN (1) CN120641401A (en)
AU (1) AU2023358062A1 (en)
IL (1) IL319486A (en)
MX (1) MX2025004094A (en)
WO (1) WO2024075051A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023358062A1 (en) * 2022-10-07 2025-03-20 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024127297A1 (en) * 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
WO2025224512A1 (en) * 2024-04-26 2025-10-30 삼진제약주식회사 Novel compound as 17-beta-hydroxysteroid dehydrogenase 13 (hsd17b13) inhibitor and pharmaceutical composition comprising same
WO2026153544A1 (en) * 2025-01-17 2026-07-23 上海隆棵药业有限公司 Hsd17b13 inhibitor, and preparation method therefor and use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3438830A1 (en) 1984-10-23 1986-04-30 Rentschler Arzneimittel PHARMACEUTICAL FORM CONTAINING NIFEDIPIN AND METHOD FOR THE PRODUCTION THEREOF
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2111065T5 (en) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited PROCEDURE TO PRODUCE A SOLID DISPERSION.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (en) 1992-03-12 2002-03-11 大正製薬株式会社 Oral pharmaceutical composition
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (en) 1995-02-14 1996-08-22 Basf Ag Solid drug preparations
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT901786E (en) 1997-08-11 2007-08-07 Pfizer Prod Inc Solid pharmaceutical dispersions with enhanced bioavailability
ID26984A (en) 1998-07-06 2001-02-22 Bristol Myers Squibb Co SULFONAMIDE COMPOUNDS AS DOUBLE ENDOTELINE ANGIOTENSIN RECEPTOR ANTAGONISTS
EA011086B9 (en) 2004-05-12 2012-08-30 Пфайзер Продактс Инк. Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
WO2010011917A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Llc SEH AND 11β-HSD1 DUAL INHIBITORS
CA2729581A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
ES2380408T3 (en) 2008-08-28 2012-05-11 Pfizer Inc. Dioxa-bicyclo derivatives [3.2.1] octane-2,3,4-triol
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
WO2010103437A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
CA2754523A1 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
GEP20135907B (en) 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
KR102438072B1 (en) 2012-01-12 2022-08-31 예일 유니버시티 Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase
US10061766B2 (en) 2015-07-27 2018-08-28 Texas State Technical College System Systems and methods for domain-specific machine-interpretation of input data
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
AU2018348195B2 (en) * 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
CA3103185A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
CA3103205A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting uchl5
AU2019371400B2 (en) 2018-11-02 2024-10-17 Dana-Farber Cancer Institute, Inc. Acetylation writer inhibitor development and uses thereof
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
AU2023358062A1 (en) * 2022-10-07 2025-03-20 Pfizer Inc. Hsd17b13 inhibitors and/or degraders

Also Published As

Publication number Publication date
WO2024075051A1 (en) 2024-04-11
CN120641401A (en) 2025-09-12
US20240150334A1 (en) 2024-05-09
KR20250075705A (en) 2025-05-28
AU2023358062A1 (en) 2025-03-20
JP2025533088A (en) 2025-10-03
MX2025004094A (en) 2025-05-02
EP4598908A1 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
JP2022540000A5 (en)
US6846928B2 (en) Compositions useful as inhibitors of protein kinases
US8669081B2 (en) Compositions useful as inhibitors of protein kinases
US11345676B2 (en) Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds
JP2017515836A5 (en)
IL274816B2 (en) The heteroaryl compounds are substituted with sulfone-pyridine alkyl amides
US9796719B2 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US7179826B2 (en) Compositions useful as inhibitors of protein kinases
US8440672B2 (en) Diphenyl substituted alkanes
ME02416B (en) ANTAGONISTS OF TRPV4
RU2018138050A (en) THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS
JP2014518214A5 (en)
JP2020521730A5 (en)
JP5301456B2 (en) Heteroaryloxyquinazoline derivatives
JP2021501220A5 (en)
US7932394B2 (en) Aryloxy-substituted benzimidazole derivatives
CA2710462A1 (en) Pyridinones and pyridazinones
US20140315878A1 (en) Chemical compounds
JP2013507366A5 (en)
JP2006519205A (en) Pyrazolopyridine derivative
JP2017500362A5 (en)
US12606562B2 (en) Pyridopyrimidines derivatives as P2X3 inhibitors
JP2017512184A5 (en)
JP2014513122A5 (en)
US7652015B2 (en) Kinase inhibitors